

BenQ Medical Technology Corp Investor Conference: 2023 Q3 Results

Stock Coke:4116 November 16, 2023

Safe Harbor Notice



We have made forward-looking statements in the presentation. Our forward-looking statements contain information regarding, among other things, our financial conditions, future expansion plans and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might not occur and our actual results could differ materially from those anticipated in these forward-looking statements.

Agenda



Company Profile

CFO

Stella Wu

2023 Q3 Financial Results

Business Update and Outlook

Vice Chairman

Harry Yang

President

Michael Kuan

Q&A



Company Profile

BMTC



BMTC is a company that focuses on 3 segments including Medical Equipment, Medical Disposables and Medical Service and creates a grand fleet of Smart Healthcare.

Established \	Year	1989
---------------	------	------

IPO Year 2015

Capital NTD 445M

No. of Employees 650+

Core Capabilities:

Medical Equipment R&D

Regulatory Compliance

TAF certified Lab

Manufacture Sites:

Taoyuan, Miaoli, Taichung,

China

R&D: Taipei, Taoyuan, Miaoli

New Subsidiaries:

K2 International Medical Inc.

K2 (Shanghai) International Medical

K2 Medical (Thailand)

PT Frismed Hoslab Indonesia

2023 First 3 Quarters Revenue

NTD 3.334B

2022 First 3 Quarters Revenue*

NTD 3.205B

2023 First 3 Quarters Revenue Breakdown by Region

Taiwan	70%
China	15%
Indonesia	6%
Other	9%



2023 Q3 Financial Results

Consolidated Statement of Comprehensive Income (Quarterly)



Unit: NT\$ Thousand

	2023 0)2	2023 Q3		QoQ	2022 Q3*		YoY
Net Sales	1,125,507	100 %	1,154,785	100%	3 %	1,116,229	100 %	3 %
Cost of Goods Sold	(808,691)	-72 %	(804,676)	-70 %		(799,328)	-72 %	
Gross Margin	316,816	28 %	350,109	30 %	11 %	316,901	28 %	10 %
Operating Expenses	(243,045)	-21 %	(248,908)	-21 %		(226,666)	-20 %	
Operating Income	73,771	7 %	101,201	9 %	37 %	90,235	8 %	12 %
Net Non-Operating Income	3,988	0 %	(1,521)	0 %		11,788	1 %	
Net Income	50,901	5 %	74,966	7%	47 %	82,076	7 %	-9 %
Net Income Attributable to BMTC	17,880	2 %	37,118	3 %	108%	34,632	3 %	7 %
EPS(NT\$) (a)	0.40		0.83			0.78		
	力 [·]							

⁽a) EPS was calculated based on total weighted-averaged outstanding shares (44,566k shares)

^{*}The restated statement

Consolidated Statement of Comprehensive Income (YTD)



Unit: NT\$ Thousand

Net Sales
Cost of Goods Sold
Gross Margin
Operating Expenses
Operating Income
Net Non-Operating Income
Net Income
Net Income Attributable to BMTC
EPS(NT\$) (a)

2023 Q3	
3,334,345	100 %
(2,362,466)	
971,879	29 %
(726,802)	
245,077	7%
6,714	
182,599	5 %
77,619	2 %
1.74	

2022 Q3	3 *	YoY
3,204,980	100 %	4 %
(2,301,433)		
903,547	28 %	8 %
(651,757)		
251,790	8 %	-3 %
92,149		
291,545	9 %	-37 %
157,193	5 %	-51 %
3.53		

⁽a) EPS was calculated based on total weighted-averaged outstanding shares (44,566k shares)

^{*}The restated statement

Consolidated Balance Sheet Highlights



Unit: NT\$ Thousand

	2023.06	.30	2023.09.30		2023.09.30		QoQ 2022.09.30*		30*	YoY
Cash & Equivalent	792,360	17 %	798,345	17%	1 %	973,849	21 %	-18 %		
Accounts Receivable	807,635	18 %	854,038	19 %	6 %	807,041	18 %	6 %		
Inventory	522,816	11 %	509,464	11 %	-3 %	468,813	10 %	9 %		
PP&E (a)	1,527,677	34 %	1,525,211	33 %	0 %	1,513,125	33 %	1 %		
Total Assets	4,555,097	100 %	4,614,002	100%	1 %	4,668,776	100%	-1 %		
Current Liabilities	1,510,428	33 %	1,343,177	29 %	-11 %	1,446,971	31 %	-7 %		
Non-Current Liabilities	607,524	13 %	1,153,536	25%	90 %	716,063	15%	61 %		
Total Liabilities	2,117,952	46 %	2,496,713	54 %	18 %	2,163,034	46 %	15%		
Equity	2,437,145	54 %	2,117,289	46 %	-13 %	2,505,742	54 %	-16 %		

⁽a) PP&E included PP&E, Investment Property and Right of Use Asset.

^{*}The restated statement



Business Update and Outlook

BMTC Winning Strategy



Current Business
Optimization



Expansion for Medication Service Scale

Smart Healthcare Strategic Placement

Business Group

BMTC 4116



Medical Equipment

524M

16%

- >Operation Room Equipment
 - Surgical Light, Surgical Table, and Pendant Tower
 - iQOR
- > Diagnostic Equipment
 - Portable / Cart Ultrasound
 - Medical Display
 - MR (Magnetic Resonance)
- >Therapeutic Equipment
 - Sport Rehabilitation
 - Pet Rehabilitation

Medical Disposables

1,927M 58%

- >IV Infusion Products
 - IV Set and Extension Set
 - Needleless Connector
 - IV Cannula
- > Anesthesia & RT Products
 - LMA& CSC
 - CPAP \ HME \ Sterile Water
- Surgical and General Disposables
 - Surgical Disposables
 - PPE
- ➤ Dialyzer
 - Hemodialysis-, Plasmapheresis
 -related product
 - Cosmeceutical

Medical Service

883M 26%

➤ Dentcare

- Digital Dentistry Equipment and Software
- 3D Clear Aligner

> Healthcare

- Hearing Service
- Smart Pharmacy

>Hospital Management

- Pharmaceuticals and Medical Consumables Integrated Supply
- Medical Equipment Leasing
- Hospital Management Consulting


Revenue

(NTD)

Business Scale









Q&A



Because it matters